Journal articleInvest New Drugs2020
Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines.
- Journal
- Invest New Drugs
- Published
- 4 December 2019
- Citations
- 3
- Type
- Article
These are the paper’s bibliographic details. A summary of its population, design, endpoints and findings, each tied to a quote, has not been written for this paper yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
abstract license unknown
Pancreatic cancer (PC) is a highly malignant cancer with poor prognosis. Although gemcitabine (GEM; 2',2'-difluoro-deoxycytidine) has been used as the first-line chemotherapeutic agent in PC treatment for decades, its limited efficacy remains a significant clinical issue, which may be resolved by GEM combination therapy. … Excerpt only: this text is the publisher’s. Read it in full at the source.